Supernus Pharmaceuticals Inc
SUPN35.740USD
+0.235+0.66%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
2.00BMarktkapitalisierung
32.32KGV TTM
mehr Informationen über Supernus Pharmaceuticals Inc Unternehmen
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.
Unternehmensinformationen
BörsenkürzelSUPN
Name des UnternehmensSupernus Pharmaceuticals Inc
IPO-datumDec 28, 2010
CEOMr. Jack A. Khattar
Anzahl der mitarbeiter674
WertpapierartOrdinary Share
GeschäftsjahresendeDec 28
Addresse9715 Key West Avenue
StadtROCKVILLE
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl20850
Telefon13018382500
Websitehttps://www.supernus.com
BörsenkürzelSUPN
IPO-datumDec 28, 2010
CEOMr. Jack A. Khattar
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jack A. Khattar
Mr. Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
2.01M
--
Mr. Frederick M. Hudson, CPA
Mr. Frederick M. Hudson, CPA
Independent Director
Independent Director
53.76K
--
Dr. Carrolee Barlow, M.D., Ph.D.
Dr. Carrolee Barlow, M.D., Ph.D.
Independent Director
Independent Director
22.57K
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Independent Director
Independent Director
18.68K
--
Mr. Frank Mottola
Mr. Frank Mottola
Senior Vice President - Quality, GMP Operations and Information Technology and Regulatory Affairs
Senior Vice President - Quality, GMP Operations and Information Technology and Regulatory Affairs
15.15K
+4.64%
Dr. Padmanabh P. Bhatt, Ph.D.
Dr. Padmanabh P. Bhatt, Ph.D.
Senior Vice President - Intellectual Property, Chief Scientific Officer
Senior Vice President - Intellectual Property, Chief Scientific Officer
12.70K
+7.63%
Mr. Timothy C. (Tim) Dec, CPA
Mr. Timothy C. (Tim) Dec, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
12.68K
+7.65%
Dr. Jonathan Rubin, M.D.
Dr. Jonathan Rubin, M.D.
Senior Vice President, Chief Medical Officer - Research and Development
Senior Vice President, Chief Medical Officer - Research and Development
9.63K
+8.32%
Mr. Charles W. Newhall, III
Mr. Charles W. Newhall, III
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Bethany L. Sensenig
Ms. Bethany L. Sensenig
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jack A. Khattar
Mr. Jack A. Khattar
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
2.01M
--
Mr. Frederick M. Hudson, CPA
Mr. Frederick M. Hudson, CPA
Independent Director
Independent Director
53.76K
--
Dr. Carrolee Barlow, M.D., Ph.D.
Dr. Carrolee Barlow, M.D., Ph.D.
Independent Director
Independent Director
22.57K
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Independent Director
Independent Director
18.68K
--
Mr. Frank Mottola
Mr. Frank Mottola
Senior Vice President - Quality, GMP Operations and Information Technology and Regulatory Affairs
Senior Vice President - Quality, GMP Operations and Information Technology and Regulatory Affairs
15.15K
+4.64%
Dr. Padmanabh P. Bhatt, Ph.D.
Dr. Padmanabh P. Bhatt, Ph.D.
Senior Vice President - Intellectual Property, Chief Scientific Officer
Senior Vice President - Intellectual Property, Chief Scientific Officer
12.70K
+7.63%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Net product sales-Qelbree
64.75M
43.21%
Net product sales - GOCOVRI
30.69M
20.48%
Net product sales-APOKYN
14.98M
10.00%
Net product sales- Trokendi XR
12.80M
8.54%
Net product sales- Oxtellar XR
10.20M
6.81%
Other
16.41M
10.96%
Nach RegionUSD
Name
Umsatz
Anteil
United States
149.82M
100.00%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Net product sales-Qelbree
64.75M
43.21%
Net product sales - GOCOVRI
30.69M
20.48%
Net product sales-APOKYN
14.98M
10.00%
Net product sales- Trokendi XR
12.80M
8.54%
Net product sales- Oxtellar XR
10.20M
6.81%
Other
16.41M
10.96%
Aktionärsstatistik
Aktualisiert: Thu, May 8
Aktualisiert: Thu, May 8
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
14.65%
The Vanguard Group, Inc.
10.99%
Armistice Capital LLC
9.28%
Dimensional Fund Advisors, L.P.
5.19%
Macquarie Investment Management
4.82%
Other
55.07%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
14.65%
The Vanguard Group, Inc.
10.99%
Armistice Capital LLC
9.28%
Dimensional Fund Advisors, L.P.
5.19%
Macquarie Investment Management
4.82%
Other
55.07%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
56.83%
Investment Advisor/Hedge Fund
30.46%
Hedge Fund
15.36%
Individual Investor
4.11%
Research Firm
2.96%
Pension Fund
1.70%
Venture Capital
0.93%
Bank and Trust
0.70%
Sovereign Wealth Fund
0.27%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
563
63.74M
113.85%
-2.63M
2025Q1
587
64.77M
115.71%
-2.86M
2024Q4
569
65.17M
116.92%
-2.59M
2024Q3
551
65.02M
117.72%
-2.14M
2024Q2
536
63.49M
115.33%
-2.27M
2024Q1
535
61.47M
111.83%
-3.83M
2023Q4
534
61.60M
112.54%
-3.30M
2023Q3
534
60.88M
111.42%
-4.46M
2023Q2
534
61.11M
111.93%
-1.60M
2023Q1
539
59.34M
108.94%
-3.56M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
8.20M
14.65%
-297.23K
-3.50%
Mar 31, 2025
The Vanguard Group, Inc.
6.15M
10.99%
+13.13K
+0.21%
Mar 31, 2025
Armistice Capital LLC
5.20M
9.28%
+360.00K
+7.44%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
2.90M
5.19%
+25.18K
+0.87%
Mar 31, 2025
Macquarie Investment Management
2.70M
4.82%
+70.76K
+2.69%
Mar 31, 2025
State Street Global Advisors (US)
2.15M
3.83%
-42.85K
-1.96%
Mar 31, 2025
Khattar (Jack A)
2.01M
3.6%
--
--
Apr 22, 2025
Renaissance Technologies LLC
1.59M
2.83%
-13.00K
-0.81%
Mar 31, 2025
Stephens Investment Management Group, LLC
1.74M
3.1%
-13.59K
-0.78%
Mar 31, 2025
Loomis, Sayles & Company, L.P.
1.44M
2.57%
-26.38K
-1.80%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Neuroscience and Healthcare ETF
4.1%
Invesco Pharmaceuticals ETF
2.62%
SPDR S&P Pharmaceuticals ETF
2.05%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.45%
Invesco S&P SmallCap Health Care ETF
1.26%
Lattice Hartford Multifactor Small Cap ETF
0.93%
iShares U.S. Pharmaceuticals ETF
0.89%
Pacer US Small Cap Cash Cows Growth Leaders ETF
0.65%
VictoryShares Small Cap Free Cash Flow ETF
0.47%
Distillate Small/Mid Cash Flow ETF
0.47%
Mehr Anzeigen
iShares Neuroscience and Healthcare ETF
Anteil4.1%
Invesco Pharmaceuticals ETF
Anteil2.62%
SPDR S&P Pharmaceuticals ETF
Anteil2.05%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil1.45%
Invesco S&P SmallCap Health Care ETF
Anteil1.26%
Lattice Hartford Multifactor Small Cap ETF
Anteil0.93%
iShares U.S. Pharmaceuticals ETF
Anteil0.89%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Anteil0.65%
VictoryShares Small Cap Free Cash Flow ETF
Anteil0.47%
Distillate Small/Mid Cash Flow ETF
Anteil0.47%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
